News

The approval was granted by the US Food and Drug Administration (FDA) and follows positive AMPLIFY Phase III trial results. This trial enrolled patients from 2019 to 2021.

The submission targets adult patients with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated locally advanced or metastatic breast cancer that has progressed after previous endocrine-based

The MoU with the National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, including its Centre of Excellence for Novel Drug Delivery Systems (CoE-NDDS), was signed at the

This partnership aims to broaden VivaMed’s validation infrastructure for AI-driven drug repurposing partnership programmes and facilitate the delivery of scientifically validated, partner-ready therapeutic candidates. It will combine Syngene’s

The partnership combines UNP’s AI-driven macrocycle platform with the worldwide development and commercialisation expertise of Novartis, aiming to produce next-generation treatments for previously undruggable targets. Under this agreement,

The collaboration will combine Mayo Clinic’s Platform architecture and clinical-genomic datasets with MSD’s virtual cell technologies to improve target identification, drive early development decisions, and enhance disease understanding.

The partnership will combine Evogene’s computational chemistry capabilities with the expertise of Dr Mark Adams’ team at QUT, focusing on therapy-resistant non-small cell lung cancer (NSCLC) and other

This combination, used alongside Lazcluze (lazertinib), is indicated as a first-line treatment for NSCLC. The therapy dosing provides clinical outcomes consistent with those of the earlier approved bi-weekly

The collaboration aims to expedite early-stage drug discovery focused on innovative therapeutics, using Teijin Pharma’s expertise in computer-aided drug design (CADD) and AI. Under the agreement, both companies